HRP20161010T1 - C5ar antagonisti - Google Patents

C5ar antagonisti Download PDF

Info

Publication number
HRP20161010T1
HRP20161010T1 HRP20161010TT HRP20161010T HRP20161010T1 HR P20161010 T1 HRP20161010 T1 HR P20161010T1 HR P20161010T T HRP20161010T T HR P20161010TT HR P20161010 T HRP20161010 T HR P20161010T HR P20161010 T1 HRP20161010 T1 HR P20161010T1
Authority
HR
Croatia
Prior art keywords
group
alkyl
heteroaryl
independently selected
aryl
Prior art date
Application number
HRP20161010TT
Other languages
English (en)
Inventor
Pingchen Fan
Kevin Lloyd Greenman
Manmohan Reddy Leleti
Yandong Li
Jay Powers
Hiroko Tanaka
Ju Yang
Yibin Zeng
Original Assignee
Chemocentryx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx, Inc. filed Critical Chemocentryx, Inc.
Publication of HRP20161010T1 publication Critical patent/HRP20161010T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)

Claims (27)

1. Spoj formule [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili rotomer; naznačen time, da C1 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R1; C2 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenata R2; C3 je odabran iz skupine koja se sastoji od C1-8 alkila, C3-8 cikloalkila, C3-8 cikloalkil-C1-4 alkila, arila, aril-C1-4 alkila, heteroarila, heteroaril-C1-4 alkila, heterocikloalkila ili heterocikloalkil-C1-4 alkila, pri čemu heterocikloalkilna skupina ili dio skupine sadržava od 1 do 3 heteroatoma odabrana iz skupine koja se sastoji od N, O i S, te pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S, a svaki C3 prema potrebi je supstituiran s 1 do 3 supstituenta R3; svaki R1 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rc, -CO2Ra, -CONRaRb, -C(O)Ra, OC(O)NRaRb, -NRbC(O)Ra, -NRbC(O)2Rc, -NRa- C(O)NRaRb, -NRaC(O)NRaRb, -NRaRb, -ORa, -S(O)2NRaRb; pri čemu je svaki Ra i Rb neovisno odabran između vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika, mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena odabrane među N, O ili S; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, a pri čemu su alifatski i ciklički dijelovi Ra, Rb i Rc prema potrebi dodatno supstituirani sa jednim do tri halogena, hidroksi, metil, amino, alkilamino i dialkilamino skupinama; i po želji, kada se dva R1 supstituenta na susjednim atomima kombiniraju tako da tvore kondenzirani peteročlani ili šesteročlani karbociklični prsten; svaki R2 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rf, -CO2Rd, -CONRdRe, -C(O)Rd, -OC(O)NRdRe, -NReC(O)Rd, -NReC(O)2Rf, - NRdC(O)NRdRe, -NRdC(O)NRdRe, -NRdRe, -ORd, i -S(O)2NRdRe; pri čemu je svaki od Rd i Re neovisno odabran iz skupine koju čine vodik, C1-8 alkil i C1-8 haloalkil, ili kada je spojen na isti atom dušika, može se kombinirati s dušikovim atomom tako da tvori peteročlani ili šesteročlani prsten sa 0 do 2 dodatna heteroatoma kao članova prstena, odabranih iz niza N, O ili S; svaki Rf neovisno je odabran iz skupine koju čine C1-8 alkil, C1-8 haloalkil, C3-6 cikloalkil, heterocikloalkil, aril i heteroaril, pri čemu su alifatski i ciklički dijelovi Rd, Re i Rf prema potrebi dodatno supstituirani s jednim do tri halogena, hidroksi, metil, amino, alkilamino i dialkilamino skupinom; svaki R3 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Ri, -CO2Rg, -CONRgRh, - C(O)Rg, -OC(O)NRgRh, -NRhC(O)Rg, -NRhC(O)2Ri, -NRgC(O)NRgRh, -NRgRh, - ORg, -S(O)2NRgRh, -X4-Rj, -X4-NRgRh , -X4-CONRgRh, -X4-NRhC(O)Rg, -NHRj i - NHCH2Rj, pri čemu je X4 C1-4 alkilen; svaki Rg i Rh neovisno je odabran iz skupine koju čine vodik, C1-8 alkil, C3-6 cikloalkil i C1-8 haloalkil, ili kada su spojeni na isti atom dušika, mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena, koji su odabrani među N, O ili S, i prema potrebi je supstituiran s jednim ili dva okso; svaki R1 neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila; a svaki Rj odabran je iz skupine koju čine C3-6cikloalkil, pirolinil, piperidinil, moRfolinil, tetrahidrofuranil i tetrahidropiranil i pri čemu su alifatski i ciklički dijelovi Rg, Rh, Ri i Rj prema potrebi dodatno supstituirani s jednom do tri skupine halogen, metil, CF3, hidroksi, amino, alkilamino i dialkilamino; i X je vodik ili CH3.
2. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da:X je vodik.
3. Spoj u skladu s patentnim zahtjevom 1 naznačen time, da spoj ima formulu: [image] ili spoj ima formulu: [image]
4. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu: [image] ili [image] pri čemu X1 je odabran iz skupine koja sadržava N, CH i CR1; indeks n je cijeli broj od 0 do 2; X2 je odabran iz skupine koja sadržava N, CH i CR2; a indeks m je cijeli broj od 0 do 2,
5. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu: [image] pri čemu je indeks p cijeli broj od 0 do 3.
6. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu: [image] pri čemu je R3 odabran iz skupine koju čine -NRgRh, -NHRj -NHCH2Rj, -X4-NRgRh, -X4- Rj i -X4-NRhCORg.
7. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C1 odabran iz skupine koju čine fenil, piridil, indolil i tiazolil, od kojih je svaki prema potrebi supstituiran s od 1 do 3 supstituenta R1; i pri čemu je svaki R1 neovisno odabran iz skupine koja se sastoji od halogena, -CN, - Rc, -NRaRb i -ORa, i pri čemu je svaki Ra i Rb neovisno odabran iz skupine koju čine vodik, C1-8 alkil i C1-8 haloalkil, ili kada su vezani na isti atom dušika, mogu se kombinirati s dušikovim atomom i tvoriti pirolidinski prsten; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila i C3-6 cikloalkila, i pri čemu su alifatski i ciklički dijelovi Ra, Rb i Rc prema potrebi dodatno supstituirani s jednom do tri hidroksi, metil amino, alkilamino i dialkilamino skupine; i po želji, kada su dva supstituenta R1 na susjednim atomima, kombiniraju se tako da tvore peteročlani ili šesteročlani kaRbociklički prsten.
8. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C2 odabran iz skupine koja sadržava fenil, naftil, piridil i indolil, od kojih je svaki prema potrebi supstituiran sa 1 do 3 R2 supstituenta; i pri čemu je svaki R2 neovisno odabran iz skupine koja se sastoji od halogena, Rf i - ORd; pri čemu je svaki Rd neovisno odabran od vodika, C1-8 alkila i C1-8 haloalkila; svaki Rf neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Rd i Rf prema potrebi dodatno supstituirani s jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino.
9. Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je C1 odabran iz skupine koju čine [image]
10. Spoj u skladu s patentnim zahtjevom 8, naznačen time, da je C2 odabran iz skupine koju čine: [image]
11. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C3 odabran iz skupine koju čine C3-6 alkil, C3-6 cikloalkil, C3-6 cikloalkilC1-2alkil, fenil, piridinil, pirazolil, piperidinil, pirolidinil, piperidinilmetil i pirolidinilmetil, od kojih je svaki prema potrebi supstituiran sa 1 do 3 supstituenta R3, pri čemu je svaki R3 neovisno odabran iz skupine koja se sastoji od halogena, -Ri -CO2Rg, -CONRgRh, -NRhC(O)Rg, - NRhC(O)2Ri, -NRgRh , -ORg, -X4-Rj -X4-NRgRh, -X4-CONRgRh, -X4-NRhC(O)Rg,, -NHRj i - NHCH2Rj, pri čemu je X4 C1-3 alkilen; svaki od Rg i Rh neovisno je odabran iz skupine koju čine vodik, C1-8 alkil, C3-6 cikloalkil i C1-8 haloalkil, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji sadržava od 0 do 1 dodatnog heteroatoma kao članove prstena odabrane iz skupine koju čine N, O ili S, i prema potrebi je supstituiran s jednim ili dva okso; svaki Ri neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila; i svaki Rj odabran je iz skupine koju čine C3-6cikloalkil, pirolinil, piperidinil, moRfolinil, tetrahidrofuranil i tetrahidropiranil, i pri čemu su alifatski i ciklički dijelovi Rg, Rh, Ri i RJ prema potrebi dodatno supstituirani s jednom do tri skupine halogen, metil, CF3, hidroksi, amino, alkilamino i dialkilamino.
12. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C3 odabran iz skupine koju čine: [image]
13. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C3 odabran iz skupine koju čine: [image]
14. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran iz skupine koju čine: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] i
15. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni spoj [image] ili njegova farmaceutski prihvatljiva sol.
16. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni spoj [image] ili njegova farmaceutski prihvatljiva sol.
17. Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni spoj [image] ili njegova farmaceutski prihvatljiva sol.
18. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 17, naznačen time, da se rabi u terapijskom liječenju ljudskog ili životinjskog tijela.
19. Farmaceutski pripravak, naznačen time, da sadržava farmaceutski prihvatljivi nosač i spoj formule [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili rotomer; pri čemu C1 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R1; C2 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R2; C3 je odabran iz skupine koja se sastoji od C1-8 alkila, C3-8 cikloalkila, C3-8 cikloalkil-C1-4 alkila, arila, aril-C1-4 alkila, heteroarila, heteroaril-C1-4 alkila, heterocikloalkila ili heterocikloalkil-C1-4 alkila, pri čemu je heterocikloalkil skupina ili njezin dio sadržava od 1 do 3 heteroatoma odabrana iz skupine koja se sastoji od N, O i S, te pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S, a svaki C3 prema potrebi je supstituiran s 1 do 3 supstituenta R3; svaki R1 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rc, -CO2Ra, -CONRaRb, -C(O)Ra, -OC(O)NRaRb, -NRbC(O)Ra, -NRbC(O)2Rc, -NRa- C(O)NRaRb, -NRaC(O)NRaRb, -NRaRb, -ORa i -S(O)2NRaRb; pri čemu je svaki Ra i Rb neovisno odabran između vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao člana prstena iz niza N, O ili S; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Ra, Rb i RC prema potrebi dodatno supstituirani s jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; i po želji, kada su dva supstituenta R1 na susjednim atomima, kombiniraju se tako da tvore peteročlani ili šesteročlani karbociklični prsten; svaki R2 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rf, -CO2Rd, -CONRdRe, -C(O)Rd, -OC(O)NRdRe, -NReC(O)Rd, -NReC(O)2Rf, - NRdC(O)NRdRe, -NRdC(O)NRdRe, -NRdRe, -ORd, i -S(O)2NRdRe; pri čemu je svaki Rd i Re neovisno odabran iz skupine koja se sastoji od vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima 0 do 2 dodatna heteroatoma kao članove prstena odabrane od N, O ili S; svaki Rf neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Rd, Re i Rf prema potrebi dodatno supstituirani s jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; svaki R3 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Ri, -CO2R9, -CONRgRh, -C(O)Rg, -OC(O)NRgRh, -NRhC(O)Rg, -NRhC(O)2Ri, - NRgC(O)NRgRh, -NRgRh, -ORg, -S(O)2NRgRh, -X4-Rj, -X4-NRgRh, -X4-CONRg Rh, - X4-NRhC(O)Rg, -NHRj i -NHCH2Rj, pri čemu je X4 C1-4 alkilen; svaki Rg i Rh neovisno je odabran iz skupine koja se sastoji od vodika, C1-8 alkila, C3-6 cikloalkila i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena odabrane između N, O ili S, i prema potrebi je supstituiran s jednim ili dva okso; svaki Ri neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila; i svaki Rj je odabran iz skupine koju čine C3-6 cikloalkil, pirolinil, piperidinil, moRfolinil, tetrahidrofuranil i tetrahidropiranil, i pri čemu su alifatski i ciklički dijelovi RG, Rh, R1 i RJ prema potrebi dodatno supstituirani s jednom do tri skupine halogen, metil, CF3, hidroksi, amino, alkilamino i dialkilamino; i X je vodik ili CH3.
20. Spoj za uporabu u postupku liječenja sisavca koji pati od ili je sklon bolestima ili poRemećajima koji uključuju patološku aktivaciju C5a receptora, naznačen time, da je bolest ili poRemećaj upalna bolest ili poRemećaj; kardiovaskularni ili cerebrovaskularni poRemećaj; autoimuni poRemećaj; ili patološka posljedica povezane sa skupinom koju čine dijabetes ovisan o inzulinu, mellitus, lupus nefropatija, Heymann nefritis, membranski nefritis, glomerulonefritis, Reakcija na osjetljivost na kontakt i upala koje su posljedica kontakta krvi s umjetnim površinama; navedeni postupak uključuje primjenu djelotvorne količine spoja na sisavcu, pri čemu navedeni spoj ima formulu: [image] ili je njegova farmaceutski prihvatljiva sol, hidrat ili rotomer; pri čemu C1 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R1; C2 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 R2 supstituenta; C3 je odabran iz skupine koja se sastoji od C1-8 alkil, C3-8 cikloalkil, C3-8 cikloalkil-C1-4 alkil, aril, aril-C1-4 alkil, heteroaril, heteroaril-C1-4 alkil, heterocikloalkil ili heterocikloalkil-C1-4 alkil, pri čemu heterocikloalkil skupina ili njezin dio sadržava od 1 do 3 heteroatoma odabrana iz skupine koja se sastoji od N, O i S, te pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S, i svaki C3 prema potrebi je supstituiran s 1 do 3 R3 supstituenta; svaki R1 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rc, -CO2Ra, -CONRaRb, -C(O)Ra, -OC(O)NRaRb, -NRbC(O)Ra, -NRbC(O)2Rc, -NRa- C(O)NRaRb, -NRaC(O)NRaRb, -NRaRb, -ORa, -S(O)2NRaRb; pri čemu je svaki Ra i Rb neovisno odabran između vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma, kao članove prstena iz niza N, O ili S; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Ra, Rb i RC prema potrebi dodatno supstituirani sa jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; i po želji, kada se dva supstituenta R1 na susjednim atomima kombiniraju tako da tvore petero ili šesteročlani karbociklični prsten; svaki R2 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rf, -CO2Rd, -CONRdRe, -C(O)Rd, -OC(O)NRdRe, -NReC(O)Rd, -NReC(O)2Rf, - NRdC(O)NRdRe, -NRdC(O)NRdRe, -NRdRe, -ORd, i -S(O)2NRdRe; pri čemu je svaki Rd i Re neovisno odabran od vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena, odabranih od N, O ili S; svaki Rf neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Rd, Re i Rf prema potrebi dodatno supstituirani s jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; svaki R3 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Ri, -CO2R9, -CONRgRh, - C(O)Rg, -OC(O)NRgRh, -NRhC(O)Rg, -NRhC(O)2Ri, -NRgC(O)NRgRh, -NRgRh, - ORg, -S(O)2NRgRh, -X4-Rj, -X4-NRgRh, -X4-CONR9 Rh, -X4-NRhC(O)Rg, -NHRj i - NHCH2Rj, pri čemu je X4 C1-4 alkilen; svaki Rg i Rh neovisno je odabran iz skupine koja se sastoji od vodika, C1-8 alkila, C3-6 cikloalkila i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena odabrane između N, O ili S, i prema potrebi je supstituiran s jednim ili dva okso; svaki Ri neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila; i svaki Rj odabran je iz skupine koju čine C3-6cikloalkil, pirolinil, piperidinil, moRfolinil, tetrahidrofuranil i tetrahidropiranil i pri čemu su alifatski i ciklički dijelovi Rg, Rh, Ri i Rj prema potrebi dodatno supstituiran s jednom do tri skupine halogen, metil, CF3, hidroksi, amino, alkilamino i dialkilamino ; i X je vodik ili CH3.
21. Spoj za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da je upalna bolest ili poRemećaj odabran iz skupine koju čine neutropenija, sepsa, septički šok, Alzheimerova bolest, multipla skleroza, moždani udar, upalne bolesti crijeva, kronična opstruktivna plućna bolest, upala povezana s opeklinama, oštećenja pluća, osteoartritis, atopični dermatitis, kronična urtikarija, ishemijsko-RepeRfuzijske ozljede, sindrom akutnog Respiratornog distResa, sindrom sistemskog upalnog odgovora, sindrom višestruke disfunkcije oRgana, odbacivanje transplantata tkiva i hiperakutno odbacivanja transplantiranih oRgana; kaRdiovaskularni ili ceRebrovaskularni poRemećaj bira se iz skupine koju čine infarkt miokaRda, koronarna tromboza, vaskularna okluzija, postoperativna vaskularna Reokluzija, ateroskleroza, traumatska ozljeda sRedišnjeg živčanog sustava i ishemijske srčane bolesti; i autoimuni poRemećaj odabran je iz skupine koju čine Reumatoidni artritis, sistemski eritematozni lupus, Guillain-BarRe sindrom, pankReatitis, lupus nefritis, lupus glomerulonefritis, psorijaza, Crohnova bolest, vaskulitis, sindrom iritabilnog crijeva, dermatomiozitis, multipla skleroza, bronhijalna astma, pemfigus, pemfigoid, skleroderma, mijastenija gravis, autoimuna hemolitička i trombocitopenična stanja, GoodpastuReov sindrom, immunovasculitis, odbacivanje tkivnih transplantata i hiperakutno odbacivanja transplantiranih oRgana.
22. Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj upalna bolest ili poRemećaj.
23. Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj kaRdiovaskularni ili ceRebrovaskularni poRemećaj.
24. Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj autoimuni poRemećaj.
25. Spoj za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da je bolest ili poRemećaj patološka posljedica povezana sa skupinom koju čine dijabetes uvjetovan inzulinom, šećerna bolest, lupus nefropatija, Heymann nefritis, membranski nefritis, glomerulonefritis, Reakcija osjetljivosti na kontakt te upala uslijed kontakta krvi s umjetnim površinama.
26. Spoj za uporabu u metodi inhibiranja stanične kemotaksije posRedovane Receptorom C5a u liječenju stanja koje je autoimuni poRemećaj, upalni poRemećaj, patološka posljedica povezana s diabetes mellitusom ovisnomo inzulinu (uključujući dijabetičku Retinopatiju), lupus nefropatija, Heymann nefritis, membranski nefritis ili drugi oblik glomerulonefritisa, Reakcije osjetljivosti na kontakt, odnosno upala uslijed kontakta krvi s umjetnim površinama koje mogu izazvati aktivaciju komplementa; bolesti povezane s ishemijskim / RepeRfuzijskim ozljedama; makularna degeneracija; kaRdiovaskularne ili ceRebrovaskularne bolesti; bolest vaskulitisa; infekcija HIV-om ili AIDS; neurodegenerativni poRemećaj; naznačen time, da podrazumijeva dovođenje u kontakt bijelih krvnih stanica sisavaca s količinom spoja koja ima modulacijski učinak na Receptor C5a, a spoj ima formulu [image] ili je njegova farmaceutski prihvatljiva sol, hidrat ili rotomer istih; pri čemu C1 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, 0 i S i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R1; C2 je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, 0 i S i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R2; C3 je odabran iz skupine koja se sastoji od C1-8 alkila, C3-8 cikloalkila, C3-8 cikloalkil- C1-4 alkila, arila, aril-C1-4 alkila, heteroarila, heteroaril-C1-4 alkila, heterocikloalkila ili heterocikloalkil C1-4 alkila, pri čemu heterocikloalkil skupina ili dio sadržava od 1 do 3 heteroatoma odabrana iz skupine koja se sastoji od N, O i S, te pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S, i svaki C3 prema potrebi je supstituiran s 1 do 3 supstituenta R3; svaki R1 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rc, - CO2Ra, -CONRaRb, -C(O)Ra, -OC(O)NRaRb, -NRbC(O)Ra, -NRbC(O)2Rc, -NRa- C(O)NRaRb, -NRaC(O)NRaRb, -NRaRb, -ORa, -S(O)2NRaRb; pri čemu je svaki Ra i Rb neovisno odabran između vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s atomom dušika kako bi tvorili petero ili šestero člani prsten koji ima od 0 do 2 dodatna heteroatoma kao članova prstena odabrana iz skupine koja se sastoji od N, O ili S; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Ra, Rb i Rc prema potrebi dodatno supstituirani sa jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; i po želji, kada se dva supstituenta R1 na susjednim atomima kombiniraju tako da tvore kondenzirani peteročlani ili šesteročlani karbociklični prsten; svaki R2 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Rf, - CO2Rd, -CONRdRe, -C(O)Rd, -OC(O)NRdRe, -NReC(O)Rd, -NReC(O)2Rf, -NRdC(O)NRdRe, -NRdC(O)NRdRe, -NRdRe, -ORd, i -S(O)2NRdRe; pri čemu je svaki od Rd i Re neovisno odabran od vodika, C1-8 alkila, i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena, odabranih od N, O ili S; svaki Rf neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila, i pri čemu su alifatski i ciklički dijelovi Rd, Re i Rf prema potrebi dodatno supstituirani s od jednom do tri skupine halogen, hidroksi, metil, amino, alkilamino i dialkilamino; svaki R3 neovisno je odabran iz skupine koja se sastoji od halogena, -CN, -Ri, - CO2R9, -CONRgRh, -C(O)Rg, -OC(O)NRgRh, -NRhC(O)Rg, -NRhC(O)2Ri, -NRgC(O)NRgRh, -NRgRh, -OR9, -S(O)2NRgRh, -X4-Rj, -X4-NRgRh, -X4-CONR9 Rh, -X4-NRhC(O)Rg, -NHRj i -NHCH2Rj, pri čemu je X4 C1-4 alkilen; svaki Rg i Rh neovisno je odabran iz skupine koja se sastoji od vodika, C1-8 alkila, C3-6 cikloalkila i C1-8 haloalkila, ili kada su spojeni na isti atom dušika mogu se kombinirati s dušikovim atomom tako da tvore peteročlani ili šesteročlani prsten koji ima od 0 do 2 dodatna heteroatoma kao članove prstena odabrane između N, O ili S, i prema potrebi je supstituiran s jednim ili dva okso; svaki Ri neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila, C3-6 cikloalkila, heterocikloalkila, arila i heteroarila; i svaki Rj je odabran iz skupine koju čine C3-6 cikloalkil, pirolinil, piperidinil, morfolinil, tetrahidrofuranil i tetrahidropiranil, i pri čemu su alifatski i ciklički dijelovi Rg, Rh, Ri i RJ prema potrebi dodatno supstituirani sa jednom do tri skupine halogen, metil, CF3, hidroksi, amino, alkilamino, i dialkilamino; i X je vodik ili CH3.
27. Spoj za uporabu u skladu s patentnim zahtjevom 26 za liječenje bolesti, naznačen time, da je bolest odabrana iz skupine koju čine sepsa kronične opstruktivne plućne bolesti (KOPB), Reumatski artritis, lupus nefritis i multipla skleroza.
HRP20161010TT 2008-12-22 2016-08-11 C5ar antagonisti HRP20161010T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13991908P 2008-12-22 2008-12-22
EP09835688.4A EP2381778B1 (en) 2008-12-22 2009-12-21 C5ar antagonists
PCT/US2009/068941 WO2010075257A1 (en) 2008-12-22 2009-12-21 C5ar antagonists

Publications (1)

Publication Number Publication Date
HRP20161010T1 true HRP20161010T1 (hr) 2016-10-07

Family

ID=42267017

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20161010TT HRP20161010T1 (hr) 2008-12-22 2016-08-11 C5ar antagonisti

Country Status (35)

Country Link
US (6) US8445515B2 (hr)
EP (4) EP3508477B1 (hr)
JP (1) JP5819730B2 (hr)
KR (1) KR101680818B1 (hr)
CN (1) CN102264227B (hr)
AR (1) AR077162A1 (hr)
AU (1) AU2009330194B2 (hr)
BR (1) BRPI0923384B1 (hr)
CA (2) CA2965223C (hr)
CO (1) CO6400172A2 (hr)
CY (1) CY1125130T1 (hr)
DK (2) DK2381778T3 (hr)
EA (1) EA020874B1 (hr)
ES (2) ES2734746T3 (hr)
FR (1) FR22C1020I2 (hr)
HK (1) HK1164639A1 (hr)
HR (1) HRP20161010T1 (hr)
HU (2) HUE030630T2 (hr)
IL (1) IL213676A (hr)
JO (1) JO3346B1 (hr)
LT (2) LT3508477T (hr)
MA (1) MA32975B1 (hr)
MX (1) MX2011006550A (hr)
NL (1) NL301166I2 (hr)
NO (1) NO2022018I1 (hr)
NZ (1) NZ594140A (hr)
PL (1) PL2381778T3 (hr)
PT (2) PT2381778T (hr)
RS (1) RS54998B1 (hr)
SG (1) SG172338A1 (hr)
SI (1) SI2381778T1 (hr)
TW (1) TWI465434B (hr)
UA (1) UA112514C2 (hr)
WO (1) WO2010075257A1 (hr)
ZA (1) ZA201104588B (hr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2965223C (en) * 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
US20110275639A1 (en) * 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
JP2013529647A (ja) * 2010-06-24 2013-07-22 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
ES2693647T3 (es) 2011-06-06 2018-12-13 Novo Nordisk A/S Anticuerpos terapéuticos
AU2012272706B2 (en) 2011-06-22 2017-07-06 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
CA2872000A1 (en) * 2012-05-04 2013-11-07 Novartis Ag Complement pathway modulators and uses thereof
DE102012109101A1 (de) 2012-09-26 2014-03-27 Endress + Hauser Gmbh + Co. Kg Füllstandsmessgerät
EP3682879B1 (en) * 2014-09-29 2022-08-03 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
WO2017123716A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
RU2748260C2 (ru) * 2016-04-04 2021-05-21 Кемосентрикс, Инк. РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
EP4272821A3 (en) 2017-04-03 2024-01-03 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
MX2019014292A (es) 2017-05-31 2022-04-07 Chemocentryx Inc Anillos 5-5 fusionados como inhibidores c5a.
BR112019025049A2 (pt) 2017-05-31 2020-06-16 Chemocentryx, Inc. Anéis 6- 5 fundidos como inibidores de c5a
KR20200020727A (ko) * 2017-06-23 2020-02-26 인플라알엑스 게엠베하 C5a 활성의 억제제를 사용한 염증 질병의 치료
AU2018310881C1 (en) 2017-07-31 2021-12-16 Novartis Ag Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP3703687A4 (en) 2017-10-30 2021-04-07 ChemoCentryx, Inc. DEUTERATED COMPOUNDS USED AS IMMUNOMODULATORS
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
KR20200110656A (ko) 2017-12-22 2020-09-24 케모센트릭스, 인크. C5aR 억제제로서의 디아릴 치환된 5,5-융합 고리 화합물
MX2020010390A (es) 2018-04-02 2021-01-15 Chemocentryx Inc Profarmacos de antagonistas de c5ar biciclicos fusionados.
CN108440513A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108558844A (zh) * 2018-05-16 2018-09-21 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108440514A (zh) * 2018-05-16 2018-08-24 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
CN108727354A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物及其在抗肿瘤药物中的应用
CN108727355A (zh) * 2018-05-16 2018-11-02 张玉叶 一种甲酰胺类衍生物、制备方法及其在抗肿瘤药物中的应用
MA52808A (fr) * 2018-06-07 2021-04-14 Chemocentryx Inc Dosage et effet d'un antagoniste de c5a avec une vasculite associée aux anca
WO2020112961A1 (en) 2018-11-30 2020-06-04 Chemocentryx, Inc. Capsule formulations
JP7360745B2 (ja) 2019-03-11 2023-10-13 インフラルクス ゲーエムベーハー C5a受容体の調節因子としての縮合ピペリジニル二環式化合物及び関連化合物
BR112021025888A2 (pt) 2019-07-10 2022-04-26 Chemocentryx Inc Indanos como inibidores de pd-l1
CA3155950A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Salt forms of a complement component c5a receptor
WO2021092286A1 (en) * 2019-11-08 2021-05-14 Chemocentryx, Inc. Amorphous form of a complement component c5a receptor
MX2022005403A (es) * 2019-11-08 2022-05-24 Chemocentryx Inc Forma cristalina de base libre de un receptor del componente c5a de complemento.
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
WO2022028586A1 (en) * 2020-08-07 2022-02-10 Kira Pharmaceuticals (Suzhou) Ltd. Compounds as c5ar inhibitors
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
WO2022078269A1 (zh) * 2020-10-16 2022-04-21 苏州科睿思制药有限公司 Avacopan的晶型及其制备方法和用途
US11844790B2 (en) 2020-10-28 2023-12-19 Chemocentryx, Inc. Methods of treating hidradenitis suppurativa
CN113957106B (zh) * 2021-11-03 2024-04-19 暨明医药科技(苏州)有限公司 一种Avacopan及其中间体的制备方法
CN117402104A (zh) * 2021-12-06 2024-01-16 重庆医科大学 阿伐可泮手性中间体的制备方法
CN114262291B (zh) * 2022-01-04 2023-05-19 重庆医科大学 一种阿伐可泮的合成方法
WO2023158722A2 (en) 2022-02-16 2023-08-24 Teva Pharmaceuticals International Gmbh Processes for preparation of avacopan and intermediates thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
JPS5331669A (en) * 1976-09-06 1978-03-25 Kissei Pharmaceut Co Ltd Novel n-acylpiperidinecaroxyanilide derivatives and their preparation
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
EP1087937A1 (en) * 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
CN1261098C (zh) 1998-08-28 2006-06-28 西奥斯股份有限公司 p38-α激酶的抑制剂
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
JP2003532726A (ja) * 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
DE60143297D1 (de) 2000-08-10 2010-12-02 Mitsubishi Tanabe Pharma Corp 3-substituierte harnstoffderivate und deren medizinische verwendung
KR100842791B1 (ko) 2000-09-14 2008-07-01 미쓰비시 타나베 파마 코퍼레이션 신규한 아미드 유도체 및 그의 의약적 용도
DE60039921D1 (de) 2000-09-29 2008-09-25 Neurogen Corp Hochaffine kleinmolekülige c5a-rezeptor-modulatoren
SE524438C2 (sv) 2000-10-05 2004-08-10 Magnus Georg Goertz Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium
WO2003008828A1 (de) * 2001-07-19 2003-01-30 Luk Lamellen Und Kupplungsbau Beteiligungs Kg System zum ansteuern einer komponente eines getriebes eines fahrzeuges unter berücksichtigung eines fluidverlustes
US7432356B2 (en) 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
CA2479928A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted biaryl amides as c5a receptor modulators
WO2003082828A1 (en) 2002-03-28 2003-10-09 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
WO2003084524A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
WO2004018460A1 (en) 2002-08-21 2004-03-04 Neurogen Corporation Amino methyl imidazoles as c5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2003290605A1 (en) 2002-11-05 2004-06-03 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
EP1638935A1 (en) * 2003-06-19 2006-03-29 Pfizer Products Inc. Nk1 antagonist
US20060154917A1 (en) 2003-07-03 2006-07-13 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
MXPA06014574A (es) * 2004-06-24 2007-03-12 Incyte Corp Piperidinas n-sustituidas y su uso como farmaceuticos.
FR2876692B1 (fr) * 2004-10-19 2007-02-23 Sanofi Aventis Sa Derives de 2-amido-4-phenylthiazole, leur preparation et leur application en therapeutique
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
BRPI0607756A2 (pt) * 2005-02-18 2010-05-18 Astrazeneca Ab composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibição de dna girase bacteriana e/ou topoisomerase iv em um animal de sangue quente, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, processo para preparar compostos ou sais farmaceuticamente aceitáveis dos mesmos
WO2007035428A1 (en) * 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) * 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
RU2458051C2 (ru) 2005-11-24 2012-08-10 ДОМПЕ ФА.Р.МА С.п.А. (r)-арилалкиламинопроизводные и содержащие их фармацевтические композиции
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
WO2008053270A2 (en) 2006-10-31 2008-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of an egfr antagonist for the treatment of glomerolonephritis
EP2178835A1 (en) * 2007-06-29 2010-04-28 Torrent Pharmaceuticals Ltd Novel substituted piperidones as hsp inducers
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) * 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP3121197A1 (en) 2008-11-10 2017-01-25 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
CA2965223C (en) 2008-12-22 2019-09-24 Chemocentryx, Inc. C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
US20120252792A1 (en) * 2009-09-17 2012-10-04 The Regents Of The University Of Michigan Methods and compositions for modulating rho-mediated gene transcription
JP2013529647A (ja) 2010-06-24 2013-07-22 ケモセントリックス,インコーポレイティド C5aRアンタゴニスト
ES2584702T3 (es) 2012-06-20 2016-09-28 Novartis Ag Moduladores de ruta del complemento y usos de los mismos
EP3682879B1 (en) 2014-09-29 2022-08-03 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
WO2017123716A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy

Also Published As

Publication number Publication date
IL213676A0 (en) 2011-07-31
CY1125130T1 (el) 2022-07-22
AU2009330194A1 (en) 2011-07-14
ZA201104588B (en) 2013-11-27
WO2010075257A1 (en) 2010-07-01
EP2381778A1 (en) 2011-11-02
PT2381778T (pt) 2016-09-19
TW201028380A (en) 2010-08-01
US20150141425A1 (en) 2015-05-21
EP3508477A1 (en) 2019-07-10
JP5819730B2 (ja) 2015-11-24
US10660897B2 (en) 2020-05-26
HUS2200025I1 (hu) 2022-06-28
NO2022018I1 (no) 2022-05-31
IL213676A (en) 2015-03-31
NL301166I2 (nl) 2022-07-06
FR22C1020I1 (fr) 2022-07-15
EP3508477B1 (en) 2021-11-10
EP4015504A1 (en) 2022-06-22
MX2011006550A (es) 2011-07-20
SI2381778T1 (sl) 2016-10-28
AU2009330194B2 (en) 2015-07-09
AR077162A1 (es) 2011-08-10
PL2381778T3 (pl) 2017-01-31
NZ594140A (en) 2013-09-27
MA32975B1 (fr) 2012-01-02
JO3346B1 (ar) 2019-03-13
DK2381778T3 (en) 2016-09-12
HUE030630T2 (en) 2017-05-29
RS54998B1 (sr) 2016-11-30
ES2577548T3 (es) 2016-07-15
LTPA2022006I1 (hr) 2022-04-25
US20100160320A1 (en) 2010-06-24
UA112514C2 (uk) 2016-09-26
EA201101009A1 (ru) 2012-01-30
LT3508477T (lt) 2022-02-10
BRPI0923384A2 (pt) 2016-06-07
US20130317028A1 (en) 2013-11-28
US20100311753A1 (en) 2010-12-09
US20190060321A1 (en) 2019-02-28
CN102264227A (zh) 2011-11-30
US8906938B2 (en) 2014-12-09
CA2965223A1 (en) 2010-07-01
CA2747522C (en) 2017-05-30
EP2381778A4 (en) 2012-09-05
EP3078658B1 (en) 2019-04-10
CA2747522A1 (en) 2010-07-01
CO6400172A2 (es) 2012-03-15
US8445515B2 (en) 2013-05-21
FR22C1020I2 (fr) 2023-05-05
ES2734746T3 (es) 2019-12-11
KR20110100661A (ko) 2011-09-14
EA020874B1 (ru) 2015-02-27
EP2381778B1 (en) 2016-06-08
PT3078658T (pt) 2019-07-16
EP3078658A1 (en) 2016-10-12
BRPI0923384B1 (pt) 2021-07-27
KR101680818B1 (ko) 2016-11-29
TWI465434B (zh) 2014-12-21
CA2965223C (en) 2019-09-24
DK3078658T3 (da) 2019-07-15
SG172338A1 (en) 2011-07-28
US20170065604A1 (en) 2017-03-09
JP2012513402A (ja) 2012-06-14
CN102264227B (zh) 2014-07-23
HK1164639A1 (en) 2012-09-28

Similar Documents

Publication Publication Date Title
HRP20161010T1 (hr) C5ar antagonisti
CA3020870C (en) Inhibitors of activin receptor-like kinase
ES2461967T3 (es) Compuestos de pirrolo[2,3-d]pirimidina
UA123905C2 (uk) Спіро[3h-індол-3,2'-піролідин]-2(1h)-онові сполуки та похідні як інгібітори мdm2-p53
CA3056906A1 (en) 6-6 fused bicyclic heteroaryl compounds and their use as lats inhibitors
CN109071454A (zh) 磺酰脲和相关化合物及其用途
JP2018520161A5 (hr)
CN105906631A (zh) 用于激酶调节的化合物和方法及其适应症
RU2008112313A (ru) Соединения ингибиторы raf и способы их применения
ZA200609277B (en) Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors
JP2007516983A5 (hr)
AR084531A1 (es) Proteinas de union a media-inmunoglobulina y sus usos
JP2011520832A5 (hr)
TW200821315A (en) Benzofuro-and benzothienopyrimidine modulators of the histamine H4 receptor
AU2021200164A1 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112020006169A2 (pt) inibidores de quinase p38 que reduzem dux4 e expressão de gene a jusante para o tratamento de fshd
TW200918541A (en) Preparation of dihydrothienopyrimidines and intermediates used therein
AU2021304045B2 (en) Immunomodulator
AU2018386223A1 (en) Small molecule degraders that recruit DCAFT15
JP2013525448A5 (hr)
CN106163523A (zh) 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的固体形式、其组合物及其使用方法
CA3075954A1 (en) Novel heterocyclic compounds as modulators of mglur7
US10538482B2 (en) Adamantane and memantine derivatives as peripheral NMDA receptor antagonists
CN106414448B (zh) 可用作s100-抑制剂的新型化合物
BR112019025866A2 (pt) compostos e composições para indução de condrogênese